Liver Transplantation for Colorectal and Neuroendocrine Liver Metastases and Hepatoblastoma. Working Group Report From the ILTS Transplant Oncology Consensus Conference

DOI HANDLE Web Site PubMed 被引用文献1件 オープンアクセス
  • Taizo Hibi
    Department of Pediatric Surgery and Transplantation, Kumamoto University Graduate School of Medical Sciences, Kumamoto, Japan.
  • Mohamed Rela
    Dr. Rela Institute & Medical Centre, Chennai, India.
  • James D. Eason
    James D. Eason Transplant Institute, Methodist/University of Tennessee Hospital, Memphis, TN.
  • Pål-Dag Line
    Department of Transplantation Medicine, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • John Fung
    University of Chicago Medicine Transplant Institute, Chicago, IL.
  • Seisuke Sakamoto
    Organ Transplantation Center, National Center for Child Health and Development, Tokyo, Japan.
  • Nazia Selzner
    Multi-Organ Transplant, Department of Medicine, University of Toronto, Toronto, Canada.
  • Kwan Man
    Department of Surgery, University of Hong Kong, Hong Kong, China.
  • R. Mark Ghobrial
    Sherrie and Alan Conover Center for Liver Disease & Transplantation, and Department of Surgery, Weill Cornell Medical College, Houston, TX.
  • Gonzalo Sapisochin
    Multi-Organ Transplant, Department of Surgery, University of Toronto, Toronto, Canada.

書誌事項

公開日
2020-06
DOI
  • 10.1097/tp.0000000000003118
公開者
Ovid Technologies (Wolters Kluwer Health)

この論文をさがす

説明

<jats:p>Liver transplantation (LT) for unresectable colorectal liver metastases has long been abandoned because of dismal prognoses. After the dark ages, advances in chemotherapy and diagnostic imaging have enabled strict patient selection, and the pioneering study from the Oslo group has contributed to the substantial progress in this field. For unresectable neuroendocrine liver metastases, LT for patients who met the Milan criteria was able to achieve excellent long-term outcomes. The guidelines further adopted in the United States and Europe were based on these criteria. For hepatoblastoma, patients with unresectable and borderline-resectable disease are considered good candidates for LT; however, the indications are yet to be defined. In the budding era of transplant oncology, it is critically important to recognize the current status and unsolved questions for each disease entity. These guidelines were developed to serve as a beacon of light for optimal patient selection for LT and set the stage for future basic and clinical studies.</jats:p>

収録刊行物

  • Transplantation

    Transplantation 104 (6), 1131-1135, 2020-06

    Ovid Technologies (Wolters Kluwer Health)

被引用文献 (1)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ